OFFICIALS LEGISLATION INTEREST GROUPS PUBLIC STATEMENTS COMMITTEES VETOES

Klobuchar urges drugmakers to remove patents FTC calls improper and inaccurate

Letter

Date: Jan. 18, 2024
Issues: Health and Health Care

BREAK IN TRANSCRIPT

"As you know, improperly listing a patent in the Orange Book can harm consumers, raise prices, and stifle competition by preventing cheaper generic drugs from entering the market for up to 30 months, and drives up the cost of entry by generic drug manufacturers by pushing them into expensive litigation before entering the market.

Patients in the United States pay more for prescription drugs than those in any other developed nation. The reasons for this are many, but one reason is the continued abuse of patent rights to extend monopoly control over a drug. While your inventions that benefit consumers deserve strong patent protections, those patents should not be used to box out generic drug competition long after legitimate patent protections have expired."

BREAK IN TRANSCRIPT


Source
arrow_upward